Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2021] FCA 416

Otsuka Pharmaceutical Co., Ltd v Generic Health Pty Ltd (No 4) [2021] FCA 416

The application for additional discovery was refused because the applicants failed to demonstrate adequate justification or relevance for the additional categories sought, particularly in light of existing comprehensive discovery, the burden and cost involved, and the lack of a new factual or legal basis; the general and specific calls for further documents were unduly onerous and not proportionate to any marginal increase in relevance to the issues.

Jurisdiction
Australia
Judgment Date
27 April 2021
Procedural Posture
Application for Additional Discovery in Enforcement Proceedings / Interlocutory
Outcome
Application for additional discovery dismissed, with costs.
Legal Topics
['practice and Procedure' 'discovery' 'patents' 'enforcement of Undertakings as to Damages']
['intellectual Property'] ['practice and Procedure' 'discovery' 'patents' 'enforcement of Undertakings as to Damages']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Application for Additional Discovery in Enforcement Proceedings / Interlocutory

Legal Issues

  1. 1 ['Whether the applicants are entitled to additional discovery from the Commonwealth according to five proposed categories of documents in the undertaking-enforcement proceedings' 'Whether the burden and relevance of the discovery sought is justified']

Ratio Decidendi

The application for additional discovery was refused because the applicants failed to demonstrate adequate justification or relevance for the additional categories sought, particularly in light of existing comprehensive discovery, the burden and cost involved, and the lack of a new factual or legal basis; the general and specific calls for further documents were unduly onerous and not proportionate to any marginal increase in relevance to the issues.

Court Disposition

Application for additional discovery dismissed, with costs.

Orders

  • ['The interlocutory application for additional discovery dated 22 December 2020 and filed by Otsuka Pharmaceutical Co., Ltd and Bristol-Myers Squibb Company be dismissed, with costs.']